Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.003 per share
-
Shares outstanding
-
792,553,191
-
Total 13F shares
-
63,630,062
-
Share change
-
+2,838,735
-
Total reported value
-
$83,982,713
-
Put/Call ratio
-
7.2%
-
Price per share
-
$1.32
-
Number of holders
-
48
-
Value change
-
+$9,810,717
-
Number of buys
-
14
-
Number of sells
-
29
Institutional Holders of Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) as of Q2 2023
As of 30 Jun 2023,
Mereo BioPharma Group plc - Ordinary Shares, par value GBP 0.003 per share (MREO) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
63,630,062 shares.
The largest 10 holders included
Rubric Capital Management LP, SUVRETTA CAPITAL MANAGEMENT, LLC, Rock Springs Capital Management LP, MANGROVE PARTNERS, 683 Capital Management, LLC, ALKEON CAPITAL MANAGEMENT LLC, BAKER BROS. ADVISORS LP, Tejara Capital Ltd, Boxer Capital, LLC, and GOLDMAN SACHS GROUP INC.
This page lists
48
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.